This report provides a comprehensive analysis of the global Amphotericin B Liposome for Injection market, which is utilized to treat serious fungal infections and leishmaniasis. The study evaluates market dynamics, growth drivers, and competitive landscapes across various specifications and applications, including hospital and clinic settings. Covering key regions such as the Americas, APAC, and Europe, the research examines major players like Gilead Sciences and SPH New Asia Pharmaceuticals to forecast industry trajectories through 2032.

Market Overview

The global Amphotericin B Liposome for Injection market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate throughout the forecast period.

Product Description

Amphotericin B Liposome for Injection is an antifungal liposomal formulation. Amphotericin B is an antifungal medication utilized for the treatment of serious fungal infections and leishmaniasis. Specific fungal infections treated with this medication include:

• Mucormycosis
• Aspergillosis
• Blastomycosis
• Candidiasis
• Coccidioidomycosis
• Cryptococcosis

Regional Market Analysis

The report provides an analysis of market expansion across several key regions from 2025 to 2032:

• United States: The market is estimated to increase steadily over the forecast period.
• China: The market is estimated to increase steadily over the forecast period.
• Europe: The market is estimated to increase steadily over the forecast period.

Market Segmentation

By Specification

• 2mg
• 10mg
• 50mg

By Application

• Hospital
• Clinic
• Others

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Key Players

The following companies have been profiled based on primary expert input and analysis of their market coverage, product portfolios, and market penetration:

• Gilead Sciences
• SPH New Asia Pharmaceuticals
• Jemincare

Market Share and Dynamics

• In 2025, the two largest global companies occupied a significant portion of the market share.
• The report analyzes key trends related to product segmentation, company formation, revenue, market share, latest developments, and M&A activity.
• Leading global companies are evaluated based on their Amphotericin B Liposome for Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints.

About the Research Report

Produced by LP Information, Inc. (LPI), the “Amphotericin B Liposome for Injection Industry Forecast” reviews total global sales in 2025 and provides a comprehensive analysis of projected sales from 2026 through 2032.

This report features:

• Detailed Analysis: Breakdown in US$ millions by region, market sector, and sub-sector.
• Strategic Insights: Evaluation of key market trends, drivers, and factors shaping the global outlook to highlight emerging opportunities.
• Methodology: A transparent approach based on hundreds of bottom-up qualitative and quantitative market inputs, offering a nuanced view of the current state and future trajectory of the industry.

Key Questions Addressed

• What is the 10-year outlook for the global Amphotericin B Liposome for Injection market?
• What factors are driving Amphotericin B Liposome for Injection market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Amphotericin B Liposome for Injection market opportunities vary by end market size?
• How does Amphotericin B Liposome for Injection break out by Specification and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Amphotericin B Liposome for Injection Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Amphotericin B Liposome for Injection by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Amphotericin B Liposome for Injection by Country/Region, 2021, 2025 & 2032

  • 2.2 Amphotericin B Liposome for Injection Segment by Specification

    • 2.2.1 2mg

    • 2.2.2 10mg

    • 2.2.3 50mg

    • 2.2.4 Amphotericin B Liposome for Injection Sales by Specification

      • 2.2.4.1 Global Amphotericin B Liposome for Injection Sales Market Share by Specification (2021-2026)
      • 2.2.4.2 Global Amphotericin B Liposome for Injection Revenue and Market Share by Specification (2021-2026)
      • 2.2.4.3 Global Amphotericin B Liposome for Injection Sale Price by Specification (2021-2026)

  • 2.3 Amphotericin B Liposome for Injection Segment by Application

    • 2.3.1 Hospital

    • 2.3.2 Clinic

    • 2.3.3 Others

    • 2.3.4 Amphotericin B Liposome for Injection Sales by Application

      • 2.3.4.1 Global Amphotericin B Liposome for Injection Sale Market Share by Application (2021-2026)
      • 2.3.4.2 Global Amphotericin B Liposome for Injection Revenue and Market Share by Application (2021-2026)
      • 2.3.4.3 Global Amphotericin B Liposome for Injection Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Amphotericin B Liposome for Injection Breakdown Data by Company

    • 3.1.1 Global Amphotericin B Liposome for Injection Annual Sales by Company (2021-2026)

    • 3.1.2 Global Amphotericin B Liposome for Injection Sales Market Share by Company (2021-2026)

  • 3.2 Global Amphotericin B Liposome for Injection Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Amphotericin B Liposome for Injection Revenue by Company (2021-2026)

    • 3.2.2 Global Amphotericin B Liposome for Injection Revenue Market Share by Company (2021-2026)

  • 3.3 Global Amphotericin B Liposome for Injection Sale Price by Company

  • 3.4 Key Manufacturers Amphotericin B Liposome for Injection Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Amphotericin B Liposome for Injection Product Location Distribution

    • 3.4.2 Players Amphotericin B Liposome for Injection Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Amphotericin B Liposome for Injection by Geographic Region

  • 4.1 World Historic Amphotericin B Liposome for Injection Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Amphotericin B Liposome for Injection Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Amphotericin B Liposome for Injection Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Amphotericin B Liposome for Injection Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Amphotericin B Liposome for Injection Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Amphotericin B Liposome for Injection Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Amphotericin B Liposome for Injection Sales Growth

  • 4.4 APAC Amphotericin B Liposome for Injection Sales Growth

  • 4.5 Europe Amphotericin B Liposome for Injection Sales Growth

  • 4.6 Middle East & Africa Amphotericin B Liposome for Injection Sales Growth

• 5 Americas

  • 5.1 Americas Amphotericin B Liposome for Injection Sales by Country

    • 5.1.1 Americas Amphotericin B Liposome for Injection Sales by Country (2021-2026)

    • 5.1.2 Americas Amphotericin B Liposome for Injection Revenue by Country (2021-2026)

  • 5.2 Americas Amphotericin B Liposome for Injection Sales by Specification (2021-2026)

  • 5.3 Americas Amphotericin B Liposome for Injection Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Amphotericin B Liposome for Injection Sales by Region

    • 6.1.1 APAC Amphotericin B Liposome for Injection Sales by Region (2021-2026)

    • 6.1.2 APAC Amphotericin B Liposome for Injection Revenue by Region (2021-2026)

  • 6.2 APAC Amphotericin B Liposome for Injection Sales by Specification (2021-2026)

  • 6.3 APAC Amphotericin B Liposome for Injection Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Amphotericin B Liposome for Injection by Country

    • 7.1.1 Europe Amphotericin B Liposome for Injection Sales by Country (2021-2026)

    • 7.1.2 Europe Amphotericin B Liposome for Injection Revenue by Country (2021-2026)

  • 7.2 Europe Amphotericin B Liposome for Injection Sales by Specification (2021-2026)

  • 7.3 Europe Amphotericin B Liposome for Injection Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Amphotericin B Liposome for Injection by Country

    • 8.1.1 Middle East & Africa Amphotericin B Liposome for Injection Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Amphotericin B Liposome for Injection Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Amphotericin B Liposome for Injection Sales by Specification (2021-2026)

  • 8.3 Middle East & Africa Amphotericin B Liposome for Injection Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Amphotericin B Liposome for Injection

  • 10.3 Manufacturing Process Analysis of Amphotericin B Liposome for Injection

  • 10.4 Industry Chain Structure of Amphotericin B Liposome for Injection

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Amphotericin B Liposome for Injection Distributors

  • 11.3 Amphotericin B Liposome for Injection Customer

• 12 World Forecast Review for Amphotericin B Liposome for Injection by Geographic Region

  • 12.1 Global Amphotericin B Liposome for Injection Market Size Forecast by Region

    • 12.1.1 Global Amphotericin B Liposome for Injection Forecast by Region (2027-2032)

    • 12.1.2 Global Amphotericin B Liposome for Injection Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Amphotericin B Liposome for Injection Forecast by Specification (2027-2032)

  • 12.7 Global Amphotericin B Liposome for Injection Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Gilead Sciences

    • 13.1.1 Gilead Sciences Company Information

    • 13.1.2 Gilead Sciences Amphotericin B Liposome for Injection Product Portfolios and Specifications

    • 13.1.3 Gilead Sciences Amphotericin B Liposome for Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Gilead Sciences Main Business Overview

    • 13.1.5 Gilead Sciences Latest Developments

  • 13.2 SPH New Asia Pharmaceuticals

    • 13.2.1 SPH New Asia Pharmaceuticals Company Information

    • 13.2.2 SPH New Asia Pharmaceuticals Amphotericin B Liposome for Injection Product Portfolios and Specifications

    • 13.2.3 SPH New Asia Pharmaceuticals Amphotericin B Liposome for Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 SPH New Asia Pharmaceuticals Main Business Overview

    • 13.2.5 SPH New Asia Pharmaceuticals Latest Developments

  • 13.3 Jemincare

    • 13.3.1 Jemincare Company Information

    • 13.3.2 Jemincare Amphotericin B Liposome for Injection Product Portfolios and Specifications

    • 13.3.3 Jemincare Amphotericin B Liposome for Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 Jemincare Main Business Overview

    • 13.3.5 Jemincare Latest Developments

• 14 Research Findings and Conclusion